-
SD 169 (indole-5-carboxamide) Assay Guide
2026-09-29
A practical, scenario-based guide to using SD 169 (indole-5-carboxamide), SKU C5850, in p38 MAPK, viability, proliferation, and apoptosis workflows. It combines formulation guidance, assay controls, data interpretation, and evidence-aware considerations for type 1 diabetes research and axonal regeneration research.
-
Monomeric Aβ–Microglia Signaling in Brain Development
2026-09-29
Kwon and colleagues identify a monomeric amyloid-β signaling pathway involving APP and Ric8a that restrains microglial immune activation during mouse neocortical development. Their findings connect disruption of this pathway with matrix proteinase activation, basement membrane degradation, neuronal ectopia, and cortical laminar defects, while also highlighting important limits in translating developmental mouse biology to Alzheimer’s disease.
-
EZ Cap™ CBEmax mRNA (m1Ψ) Assay Guide
2026-09-28
A scenario-based guide to designing viability, proliferation, and cytotoxicity readouts around EZ Cap™ CBEmax mRNA (m1Ψ), SKU R1044. It separates delivery-related stress from editing biology, outlines practical controls, and connects assay interpretation to published base-editing evidence.
-
TMRE Mitochondrial Membrane Potential in Energy Failure
2026-09-28
The TMRE mitochondrial membrane potential assay kit can reveal early changes in mitochondrial polarization, but a fluorescence shift is not a complete readout of energy failure or cell-death mechanism. This article connects TMRE interpretation to a recent study of sodium-driven mitochondrial dysfunction and outlines how to build a more informative assay.
-
Asunaprevir Workflows for HCV Protease Research
2026-09-27
Use Asunaprevir (BMS-650032) to connect direct NS3/4A protease inhibition with downstream HCV RNA replication readouts. This guide pairs a practical assay workflow with controls and troubleshooting, while clearly separating HCV evidence from a cross-disciplinary cancer-screening study.
-
Gut Dysbiosis and α-Synuclein Pathology in Parkinson’s
2026-09-26
In a rotenone-induced mouse model, antibiotic depletion and fecal microbiota transplantation provide evidence that gut microbiota status contributes to intestinal inflammation, motor deficits, and α-synuclein-related pathology. The findings connect microbiota disruption with C/EBPβ/AEP signaling in the substantia nigra, while leaving the responsible microbial features and the precise molecular sequence to be resolved.
-
Poria cocos Polysaccharides, NRF2, and Liver Ferroptosis
2026-09-25
Zhou and colleagues report that Poria cocos polysaccharides (PCP) alleviate experimental alcoholic liver injury alongside changes in NRF2 signaling, oxidative stress, inflammation, and ferroptosis-associated measures. By combining animal and cell models with ferrostatin-1 and the NRF2 inhibitor ML385, the study tests pathway involvement, while leaving important questions about mechanism, model detail, and translation to human disease open.
-
Irinotecan in Tumor–Stroma Drug Response Models
2026-09-25
Explore how Irinotecan (CPT-11) can be evaluated in tumor–stroma models without confusing cancer-cell sensitivity with microenvironment effects. A patient-derived gastric assembloid study offers practical guidance for designing and interpreting colorectal cancer research assays.
-
ML385 Workflows for NRF2 Pathway Research
2026-09-24
Use ML385 to test whether NRF2 activity contributes to antioxidant defenses, inflammatory phenotypes, or cancer therapeutic resistance—not simply whether a treatment changes cell viability. This workflow pairs a concentration-and-time pilot with orthogonal pathway readouts and highlights a recent osteoclast study that used ML385 to test NRF2 dependence outside cancer models.
-
TMRE Assays for Sodium-Driven Mitochondrial Failure
2026-09-24
The TMRE mitochondrial membrane potential assay kit can reveal how sodium stress alters mitochondrial polarization—but fluorescence alone cannot identify the cause or type of cell death. This article connects TMRE readouts to recent findings on sodium-driven energy failure and outlines a more defensible experimental strategy.
-
ABT-737 for Mitochondrial Apoptosis Assays
2026-09-23
Use ABT-737 to probe BCL-2-family dependence and apoptosis in cancer models, then pair cell-death measurements with mitochondrial mRNA imaging to ask what changes inside mitochondria. This workflow connects a practical BH3-mimetic perturbation to super-resolution methods while clearly separating established findings from experiments that still need validation.
-
GSTA1 Amplifies α-Amanitin Liver Injury
2026-09-23
This study identifies GSTA1 as an unexpected pathogenic driver in α-amanitin-induced hepatotoxicity rather than a uniformly protective antioxidant enzyme. By combining mouse toxicology, multi-omics, interaction assays, and genetic experiments, the authors link GSTA1 upregulation to glutathione depletion, reactive oxygen species accumulation, and hepatocyte injury.
-
STT3A–FCN3 Glycosylation in HCC Progression
2026-09-22
The reference study identifies an STT3A–FCN3–APC/Wnt/β-catenin pathway linking aberrant N-glycosylation to regulatory T-cell activation and hepatocellular carcinoma progression. Its combination of site-directed glycosylation analysis, genetic perturbation, cell assays, and xenograft experiments provides a framework for distinguishing global glycosylation effects from FCN3-specific mechanisms.
-
Sodium-Driven Mitochondrial Failure in NECSO
2026-09-22
Qiao and colleagues identify mitochondrial energy failure as the mechanistic link between TRPM4-mediated sodium influx and necrosis by sodium overload (NECSO). Their findings connect mitochondrial sodium accumulation, NCLX-dependent calcium loss, impaired oxidative metabolism, ATP depletion, and Na/K-ATPase failure into a coherent pathway that explains cell swelling and lysis.
-
(Z)-4-Hydroxytamoxifen in Relapse Models
2026-09-21
A mechanistic and translational framework for using (Z)-4-Hydroxytamoxifen to interrogate estrogen receptor biology while strategically integrating proliferation-tracing models of breast cancer relapse.